-

North America CRISPR Markets 2019-2020 & Forecast to 2028 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "North America CRISPR Market 2019-2028" report has been added to ResearchAndMarkets.com's offering.

This report on the North American CRISPR market, depicts that the industry will bloom at a CAGR of 23.85% over the estimated period 2019-2028.

North America is the largest CRISPR (Clustered Regularly Interspaced Short Palindrome Repeats) market in the world. This growth is contributed by the growing biotechnology and pharmaceutical sectors. Due to the rising applications in human stem cells & genetic engineering and the growing demand for genetically modified organisms, there is an increased demand for the CRISPR market in the region.

The CRISPR market in North America is growing at a considerable pace. It finds its applications in human stem cells, genetic engineering, academic institutes, genome editing, biotechnology companies, pharmaceutical companies and research & development institutes. By using CRISPR technology, various drugs can be produced, which can improve the effectiveness of treatment and vaccines. Other factors aiding the CRISPR market growth in North America are the high investments in the technology, along with the growing development in research activities in countries like the US and Canada.

The United States is an attractive market for the healthcare industry, due to the high occurrence of lifestyle-oriented diseases and the escalating healthcare expenditure in the country. These factors are likely to push the demand for the CRISPR market in the country in the coming years.

Competitive Outlook

Some noteworthy companies in the CRISPR market are Applied StemCell, Editas Medicine, GeneCopoeia Inc, Intellia Therapeutics Inc, Horizon Discovery Ltd, Addgene, Genedata AG, Origene Technologies Inc, Lonza, Cellectis and DiaCarta.

Key Topics Covered:

1. North America CRISPR Market - Summary

2. Industry Outlook

2.1. Market Definition

2.2. Porter's Five Forces Model

2.3. Regulatory Outlook

2.4. Value Chain Outlook

2.5. Supply Chain Outlook

2.6. Timeline of CRISPR Market

2.7. Parent Market Outlook

2.8. Key Insight

2.9. Market Attractiveness Index

2.10. Market Drivers

2.10.1. Growing Lifestyle-Oriented Diseases

2.10.2. Surging Prevalence of Genetic Diseases

2.10.3. Increasing Application of Drugs

2.10.4. Rising Aging Population

2.10.5. Incidence of Genetic Ailments

2.11. Market Restraints

2.11.1. Ethical and Social Issues Associated With CRISPR Technology

2.11.2. Changing Regulatory Environment

2.12. Market Opportunities

2.12.1. Increased Demand for CRISPR

2.12.2. Advancements in the Applications of Gene-Based Therapy

2.13. Market Challenges

2.13.1. Alternative Technologies

2.13.2. Lack of Awareness Regarding the Technology

3. CRISPR Market Outlook - By Product

3.1. Plasmids

3.2. Vectors

3.3. Proteins

3.4. Design Tools

3.5. Grna

3.6. Control Kits

3.7. Library

3.8. Other Products

4. CRISPR Market Outlook - By Application

4.1. Genome Editing/Genetic Engineering

4.2. Grna Database/Gene Library

4.3. CRISPR Plasmid

4.4. Human Stem Cells

4.5. Cell Line Engineering

5. CRISPR Market Outlook - By End-User

5.1. Therapeutics & Drug Discovery

5.2. Biological Research

5.3. Agricultural Biotech

5.4. Industrial Biotech

6. CRISPR Market - North America

6.1. the United States

6.2. Canada

7. Company Profile

7.1. Addgene

7.2. Applied Stemcell

7.3. Caribou Biosciences Inc

7.4. Cellectis

7.5. CRISPR Therapeutics

7.6. Diacarta

7.7. Editas Medicine

7.8. Genecopoeia Inc

7.9. Genedata Ag

7.10. Genscript

7.11. Horizon Discovery Ltd

7.12. Integrated Dna Technologies Inc

7.13. Intellia Therapeutics Inc

7.14. Lonza

7.15. New England Biolabs

7.16. Origene Technologies Inc

7.17. Precision Biosciences

7.18. Sangamo Therapeutics

7.19. Sigma-Aldrich (Merck Kgaa)

7.20. Thermo Fisher Scientific Inc

7.21. Transposagen Bio (Hera Biolabs)

8. Research Methodology & Scope

For more information about this report visit https://www.researchandmarkets.com/r/85n3qe

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Malaysia Defense Industry Report 2025: $4.8 Billion Allocation in 2025 Reflects 6.0% CAGR Growth Momentum - Forecast to 2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Malaysia Defense Market - Size and Trends, Budget Allocation, Regulations, Key Acquisitions, Competitive Landscape and Forecast, 2025-2030" report has been added to ResearchAndMarkets.com's offering. The report provides the market size forecast and the projected growth rate for the next five years. The report covers industry analysis including the key market drivers, emerging technology trends, and major challenges faced by market participants. It also offers insig...

France Defense Industry Report 2025: Defense Expenditure Driven by Domestic Modernization Programs, Russia and the Invasion of Ukraine and NATO Alliance - Forecast to 2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "France Defense Market - Size and trends, budget allocation, regulations, key acquisitions, competitive landscape and forecast, 2025-2030" report has been added to ResearchAndMarkets.com's offering. The report provides the market size forecast and the projected growth rate for the next five years. The report covers industry analysis including the key market drivers, emerging technology trends, and major challenges faced by market participants. It also offers insight...

$43.4 Bn Orphan Drugs Service Markets 2019-2024, 2024-2029F, 2034F - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Orphan Drugs Service Market Report 2025" has been added to ResearchAndMarkets.com's offering. The global orphan drugs service market is witnessing unprecedented growth, reflecting the increasing focus on rare diseases, investment in biopharmaceutical research, and enhanced collaborations between healthcare providers and researchers. From $37.05 billion in 2024, the market is projected to soar to $43.4 billion by 2025, with a robust CAGR of 17.1%. Growth drivers inc...
Back to Newsroom